Standard Biotools (LAB) EBT Margin (2010 - 2026)
Standard Biotools' (LAB) quarterly EBT Margin came in at 106.62% in Q2 2026, down 2261.0% year-over-year from 4.93% in Q2 2025, and down 54.27% quarter-over-quarter from 69.11% in Q1 2026.
Powered by 
Analysis
Standard Biotools (LAB) EBT Margin (2010 - 2026) Analysis & Trends
Standard Biotools (LAB) has reported EBT Margin for 17 consecutive years, with 106.62% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBT Margin fell 2261.0% year-over-year to 106.62% in Q2 2026; TTM through Jun 2026 was 107.55%, a 572.0% decrease from a year earlier, with the FY2025 full-year figure at 113.33%, down 1400.0% from the prior year.
- EBT Margin was 106.62% for Q2 2026 at Standard Biotools, down from 69.11% in the prior quarter.
- Over five years, EBT Margin peaked at 60.5% in Q2 2023 and troughed at 346.98% in Q2 2022.
- A 5-year average of 118.81% and a median of 95.65% in 2024 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin plunged 28719 bps in 2022 and surged 28647 bps in 2023, its largest moves.
- Over 5 years, EBT Margin stood at 76.88% in 2022, then advanced by 8 bps to 70.73% in 2023, then slumped by 53 bps to 108.57% in 2024, then rose by 15 bps to 92.59% in 2025, then retreated by 15 bps to 106.62% in 2026.
- The last three EBT Margin figures came in at 106.62% (Q2 2026), 69.11% (Q1 2026), and 92.59% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 225.12 Bn | 221.06 Bn | 8.34 Bn | 16.04% |
| 2 | Danaher | 144.34 Bn | 139.99 Bn | 3.61 Bn | 17.21% |
| 3 | Agilent Technologies | 41.01 Bn | 39.25 Bn | 1.04 Bn | 23.64% |
| 4 | Illumina | 31.14 Bn | 29.97 Bn | 770.00 Mn | 22.43% |
| 5 | Revvity | 13.89 Bn | 12.86 Bn | 416.87 Mn | 8.71% |
| 6 | Bio-Techne | 11.27 Bn | 11.00 Bn | 211.39 Mn | 22.01% |
| 7 | Bio-Rad Laboratories | 10.13 Bn | 8.51 Bn | 345.80 Mn | 83.27% |
| 8 | Repligen | 9.34 Bn | 8.33 Bn | 110.04 Mn | 6.93% |
| 9 | 10x Genomics | 8.67 Bn | 8.12 Bn | 112.50 Mn | -12.34% |
| 10 | Standard Biotools | 282.29 Mn | -194.42 Mn | 10.54 Mn | -106.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -106.62% |
| Mar 31, 2026 | -69.11% |
| Dec 31, 2025 | -92.59% |
| Sep 30, 2025 | -168.27% |
| Jun 30, 2025 | -84.01% |
| Mar 31, 2025 | -116.16% |
| Dec 31, 2024 | -108.57% |
| Sep 30, 2024 | -98.71% |
| Jun 30, 2024 | -112.95% |
| Mar 31, 2024 | -70.33% |
| Dec 31, 2023 | -70.73% |
| Sep 30, 2023 | -82.58% |
| Jun 30, 2023 | -60.50% |
| Mar 31, 2023 | -66.01% |
| Dec 31, 2022 | -76.88% |
| Sep 30, 2022 | -117.52% |
| Jun 30, 2022 | -346.98% |
| Mar 31, 2022 | -290.00% |
| Sep 30, 2021 | -57.86% |
| Jun 30, 2021 | -59.79% |